ELI LILLY AND COMPANY Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ELI LILLY AND COMPANY (LLY) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $210.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-02-19
- ELI LILLY AND COMPANY right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $33.40M.
- ELI LILLY AND COMPANY right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-09-30 was $1.60M.
- ELI LILLY AND COMPANY right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-06-30 was $11.10M.
- ELI LILLY AND COMPANY right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-03-31 was $35.10M.
- ELI LILLY AND COMPANY right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $210.00M, a 64.41% decline from fiscal 2023.
- ELI LILLY AND COMPANY right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $590.00M, a 279.67% increase from fiscal 2022.
- ELI LILLY AND COMPANY right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $155.40M, a 4.95% decline from fiscal 2021.
- ELI LILLY AND COMPANY right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $163.50M, a 19.60% increase from fiscal 2020.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $210.00M 10-K · filed 2025-02-19 | |||
| 2023-12-31 | $590.00M 10-K · filed 2025-02-19 | |||
| 2022-12-31 | $155.40M 10-K · filed 2025-02-19 | |||
| 2021-12-31 | $163.50M 10-K · filed 2024-02-21 | |||
| 2020-12-31 | $136.70M 10-K · filed 2023-02-22 | |||
| 2019-12-31 | $33.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $35.00M derived: sum of 2 quarters · filed 2022-02-23 | $46.10M derived: sum of 3 quarters · filed 2022-02-23 | $81.20M 10-K · filed 2022-02-23 |
| 2019-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-25 | $12.70M derived: sum of 2 quarters · filed 2019-10-25 | $47.80M 10-Q · filed 2019-10-25 | |
| 2019-06-30 | $11.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $46.20M 10-Q · filed 2019-08-02 | ||
| 2019-03-31 | $35.10M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |